Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Atomo Diagnostics (AT1) has received an unscheduled purchase order from French company NG Biotech to supply 422,000 COVID-19 blood test devices
  • The additional order comes after the French company’s earlier purchases of 947,200 devices between late March and mid-April – bringing the total orders to 1.369 million devices
  • The rapid blood tests are used to detect the presence of COVID-19 antibodies, and can deliver results in just 15 minutes
  • The companies are now in talks about expanding the sales footprint for the tests in other territories, including the U.S., pending FDA approval
  • Atomo is currently ramping up production capacity, with the first phase scheduled to come online in July this year
  • Atomo Diagnostics stocks have risen 7.9 per cent off the back of this morning’s announcement, with shares priced at 48 cents each

Rapid blood test manufacturer Atomo Diagnostics (AT1) has received an unscheduled purchase order from French diagnostics company NG Biotech to supply 422,000 COVID-19 blood test devices.

The additional order comes after the French company’s earlier purchases of 947,200 devices between late March and mid-April – bringing the total orders to 1.369 million devices.

The rapid blood tests are used to detect the presence of COVID-19 antibodies, and can deliver results in just 15 minutes.

The NG Biotech rapid test is CE Marked for professional use for COVID-19 testing in Europe — meaning it has approval for sale across the Eurozone.

The companies are now in talks about expanding the sales footprint for the tests in other territories.

Atomo Co-Founder and Managing Director John Kelly says the added demand means the company will have to increase production.

“We are excited about continuing to scale up our supply to NG Biotech as it starts to rollout the COVID-19 rapid test in France,” he said.

“We remain in active discussions with NG Biotech regarding the potential expansion of our COVID-19 partnership across other territories and intended uses,” John noted.

“Discussions with two U.S.-based companies in relation to commercialisation of COVID-19 tests (subject to FDA approval) are progressing positively and we continue to have discussions related to the supply of COVID-19 tests to the Australian market.”

Atomo Co-Founder and Managing Director John Kelly

Atomo is currently ramping up production capacity, with the first phase scheduled to come online in July this year, and further increases planned for the second half of 2020.

Atomo Diagnostics stocks have risen 7.9 per cent off the back of this morning’s announcement, with shares priced at 48 cents each as at 11:55 am AEST.

AT1 by the numbers
More From The Market Herald
The Market Herald Video

" Proteomics International Laboratories (ASX:PIQ) signs binding LOI with Sonic Healthcare USA

Proteomics International Laboratories (ASX:PIQ) signs a binding letter of intent to introduce PromarkerD to the US.
The Market Herald Video

" Dimerix (ASX:DXB) submits new patent family application for DMX-700

Dimerix (ASX:DXB) has submitted a new patent family application for its flagship DMX-700 used to treat…
The Market Herald Video

" Mesoblast (ASX:MSB) raises US$45m for lead products

Mesoblast (ASX:MSB) completes its private placement which raised US$45 million (A$64.5 million).
The Market Herald Video

" Imugene (ASX:IMU) sees “positive signs” from lung cancer trial, presents data at 2022 world conference

Imugene (ASX:IMU) presents new data from its PD1-Vaxx trial in non-small cell lung cancer patients at…